PL1981981T3 - Przeciwciało monoklonalne anty-Met, jego fragmenty i wektory do leczenia nowotworów oraz odpowiednie produkty - Google Patents

Przeciwciało monoklonalne anty-Met, jego fragmenty i wektory do leczenia nowotworów oraz odpowiednie produkty

Info

Publication number
PL1981981T3
PL1981981T3 PL07704350T PL07704350T PL1981981T3 PL 1981981 T3 PL1981981 T3 PL 1981981T3 PL 07704350 T PL07704350 T PL 07704350T PL 07704350 T PL07704350 T PL 07704350T PL 1981981 T3 PL1981981 T3 PL 1981981T3
Authority
PL
Poland
Prior art keywords
monoclonal antibody
tumors
vectors
treatment
met monoclonal
Prior art date
Application number
PL07704350T
Other languages
English (en)
Inventor
Paolo Maria Comoglio
Elisa Vigna
Silvia Giordano
Original Assignee
Metheresis Translational Res Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Res Sa filed Critical Metheresis Translational Res Sa
Publication of PL1981981T3 publication Critical patent/PL1981981T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
PL07704350T 2006-02-06 2007-02-05 Przeciwciało monoklonalne anty-Met, jego fragmenty i wektory do leczenia nowotworów oraz odpowiednie produkty PL1981981T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06101345 2006-02-06
EP07704350A EP1981981B1 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
PCT/EP2007/051066 WO2007090807A1 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products

Publications (1)

Publication Number Publication Date
PL1981981T3 true PL1981981T3 (pl) 2011-11-30

Family

ID=36616994

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07704350T PL1981981T3 (pl) 2006-02-06 2007-02-05 Przeciwciało monoklonalne anty-Met, jego fragmenty i wektory do leczenia nowotworów oraz odpowiednie produkty

Country Status (21)

Country Link
US (2) US8388958B2 (pl)
EP (2) EP1981981B1 (pl)
JP (1) JP5306828B2 (pl)
KR (1) KR101429297B1 (pl)
CN (1) CN101379192B (pl)
AT (1) ATE514715T1 (pl)
AU (1) AU2007213804B2 (pl)
BR (1) BRPI0707480A8 (pl)
CA (1) CA2638889C (pl)
CY (1) CY1111884T1 (pl)
DK (1) DK1981981T3 (pl)
EA (1) EA015580B1 (pl)
ES (1) ES2368864T3 (pl)
IL (1) IL192879A (pl)
MX (1) MX2008009833A (pl)
PL (1) PL1981981T3 (pl)
PT (1) PT1981981E (pl)
SG (2) SG169382A1 (pl)
SI (1) SI1981981T1 (pl)
WO (1) WO2007090807A1 (pl)
ZA (1) ZA200806559B (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
IL198545A0 (en) 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP2127683A1 (en) * 2008-05-29 2009-12-02 Metheresis Translational Research SA Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
CN107739407B (zh) 2010-03-10 2021-07-06 根马布股份公司 抗c-MEt的单克隆抗体
WO2011125458A1 (ja) 2010-04-02 2011-10-13 富士レビオ株式会社 抗癌剤の効果の診断用マーカー
EP2576622A4 (en) * 2010-06-01 2013-11-27 Univ Monash ANTIBODIES AGAINST RECEPTOR TYROSINE KINASE C-MET
JP5955322B2 (ja) * 2010-09-03 2016-07-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 抗ｃ−ｍｅｔ抗体及びその使用方法
ES2594493T3 (es) 2010-11-03 2016-12-20 arGEN-X BV Anticuerpos anti-c-Met
DK2500036T3 (da) * 2011-03-18 2014-08-04 Metheresis Translational Res Sa MET-hæmmere til øgning af virkningen af radioterapi
EP2758430A4 (en) 2011-09-20 2015-06-03 Lilly Co Eli ANTI-C-MET ANTIBODY
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
JP2014533700A (ja) 2011-11-21 2014-12-15 ジェネンテック， インコーポレイテッド 抗ｃ−ＭＥＴ抗体の精製
US20150147274A1 (en) * 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
JP6429771B2 (ja) * 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
ITTO20130012A1 (it) 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
BR112017005202A2 (pt) 2014-09-16 2017-12-12 Symphogen As anticorpos anti-met e composições
WO2016149116A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Antibodies targeting s100b and methods of use
CN113150147A (zh) * 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
CA3036643C (en) * 2016-09-29 2021-10-26 Mitsubishi Tanabe Pharma Corporation Cmet monoclonal binding agents, drug conjugates thereof and uses thereof
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN106872695B (zh) * 2017-01-20 2019-06-11 中山大学 一种h7亚型禽流感病毒血凝素抗体间接elisa检测试剂盒
IT201800000535A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
IT201800003875A1 (it) 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
KR20200138288A (ko) * 2018-03-28 2020-12-09 미쓰비시 타나베 파마 코퍼레이션 cMET 모노클로날 결합제의 약물 접합체, 및 그의 용도
IT201800009282A1 (it) 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
EP4031574A1 (en) 2019-09-16 2022-07-27 Regeneron Pharmaceuticals, Inc. Radiolabeled met binding proteins for immuno-pet imaging

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6814962B1 (en) 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Also Published As

Publication number Publication date
SI1981981T1 (sl) 2012-01-31
US8388958B2 (en) 2013-03-05
US20090285807A1 (en) 2009-11-19
CA2638889A1 (en) 2007-08-16
EP1981981A1 (en) 2008-10-22
CY1111884T1 (el) 2015-11-04
EA200870234A1 (ru) 2009-02-27
IL192879A (en) 2014-02-27
JP5306828B2 (ja) 2013-10-02
AU2007213804A8 (en) 2008-08-28
CN101379192B (zh) 2013-07-31
KR20090013745A (ko) 2009-02-05
AU2007213804B2 (en) 2012-12-13
MX2008009833A (es) 2008-10-23
CA2638889C (en) 2015-06-02
SG169383A1 (en) 2011-03-30
EP1981981B1 (en) 2011-06-29
SG169382A1 (en) 2011-03-30
BRPI0707480A2 (pt) 2011-05-03
AU2007213804A1 (en) 2007-08-16
US20120134996A1 (en) 2012-05-31
EP2192188A1 (en) 2010-06-02
ATE514715T1 (de) 2011-07-15
PT1981981E (pt) 2011-10-04
KR101429297B1 (ko) 2014-08-12
CN101379192A (zh) 2009-03-04
EA015580B1 (ru) 2011-10-31
ZA200806559B (en) 2012-12-27
JP2009526010A (ja) 2009-07-16
BRPI0707480A8 (pt) 2022-11-08
WO2007090807A1 (en) 2007-08-16
ES2368864T3 (es) 2011-11-23
US8729043B2 (en) 2014-05-20
DK1981981T3 (da) 2011-09-26
IL192879A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
IL192879A0 (en) Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
IL243376A0 (en) Antagonistic antibody against epha2 for cancer treatment
ZA200805158B (en) Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
SI1802625T1 (sl) Disubstituirani pirazolobenzodiazepini, koristni kot inhibitorji za cdk2 in angiogenezo ter za zdravljenje prsnega raka, raka kolona, pljuäśnega rakain raka prostate
CY1115571T1 (el) Νεες ενωσεις και μεθοδοι για θεραπεια
CY1113209T1 (el) Νεα παραγωγα πυρρολο [3,2-d] πυριμιδιν-4-ονης και η χρηση τους στη θεραπεια
IL173386A0 (en) Use of adcc-optimized antibodies for treating weak patients
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
EA200970738A1 (ru) Ингибиторы активности akt
EP2063897A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP2063896A4 (en) KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES
EP1814854A4 (en) Cationic cereals and analogues thereof, and their use for the prevention or treatment of cancer
MY153198A (en) Inhibitors of protein aggregation
TW200624426A (en) BACE inhibitors
PL1888653T3 (pl) Sposób polimeryzacji olefin
HK1208701A1 (en) Means for inhibiting the expression of protein kinase
WO2007135546A3 (en) TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
WO2008110379A3 (en) Monoclonal antibodies for treatment of cancer
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
IL200410A0 (en) Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
UA100545C2 (ru) Гидроксилированные пиримидил циклопентаны как ингибиторы протеинкиназы акт
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors